Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 15/20 | 0.46 |
| ▸ | JAK1 | P23458 | 12/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602499 | 0.86 | IGF1R (0.51) | IGF1RJAK2JAK1JAK3AURKA | |
| SCHEMBL3604003 | 0.84 | PTK2 (0.49) | IGF1RJAK1JAK3AURKALCK | |
| SCHEMBL4621383 | 0.83 | HTR2A (0.49) | JAK2JAK3EGFRAXL | |
| SCHEMBL3600363 | 0.82 | LCK (0.39) | IGF1RJAK2JAK1JAK3AURKA | |
| SCHEMBL3610904 | 0.82 | USP30 (0.46) | IGF1RJAK2JAK1JAK3AURKA | |
| SCHEMBL3305278 | 0.81 | IKBKB (0.45) | AURKA | |
| SCHEMBL3603632 | 0.79 | KMT2A (0.41) | JAK1JAK3AURKALCK | |
| SCHEMBL4623357 | 0.78 | JAK2 (0.48) | IGF1RJAK2JAK3EGFRAXL | |
| SCHEMBL3298098 | 0.78 | AURKA (0.72) | AURKA | |
| Hydrochloric Acid SCHEMBL4881375 | 0.78 | JAK2 (0.47) | IGF1RJAK2JAK3EGFRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| EP-2104673-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | claimed |
| WO-2008099072-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | claimed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2104673-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008099072-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099072-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | IKBKB, CDK2, IKBKE | IGF1R 1100/4885JAK2 97/4885JAK1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.